Home / Recalls / Mayne Pharma Inc / D-0098-2018

D-0098-2018 Class II Terminated

Recalled by Mayne Pharma Inc — Greenville, NC

FDA drug recall D-0098-2018 was initiated by Mayne Pharma Inc on Nov 9, 2017 and is designated Class II. Reason for recall: Failed Dissolution Specifications. The recall status is terminated (terminated May 11, 2020). Affected quantity: 11,364 bottles.

Recall Details

Product Type: Drugs
Report Date: Dec 6, 2017
Initiation Date: Nov 9, 2017
Termination Date: May 11, 2020
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 11,364 bottles

Product Description

Liothyronine Sodium Tablets, USP 25 mcg ,100-count bottles, Rx Only, Distributed by Perrigo Minneapolis, MN 55427, NDC 0574-0222-01

Reason for Recall

Failed Dissolution Specifications.

Distribution Pattern

Nationwide within USA

Code Information

Lot: #:16F649, Exp: May 2018

Source

Dataset: openFDA drug recall enforcement reports
FDA record: This recall in openFDA (JSON)
Enforcement Report: Search FDA's Enforcement Report for D-0098-2018
openFDA file date: Nov 3, 2026
Loaded by RegDataLab: Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Other recalls by Mayne Pharma Inc

D-1152-2022 Class II — Clonidine Transdermal System, USP 0.3 mg/day, 4 Patches (NDC 51862-455-01) per… (Jun 9, 2022)
D-0387-2022 Class II — Lexette (halobetasol propionate) Topical Foam, 0.05% 50 g canisters, Rx ONLY… (Jan 14, 2022)
D-0998-2020 Class II — Carbidopa and Levodopa Tablets, USP 25 mg/250mg, 100 ct bottle, Rx Only, Mayne… (Mar 2, 2020)
D-1129-2018 Class III — Oxycodone and Acetaminophen Tablets, USP, 5 mg*/325 mg, 100-count bottle, Rx… (Aug 21, 2018)
D-0616-2018 Class III — Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne… (Mar 21, 2018)